Information Provided By:
Fly News Breaks for March 20, 2019
BHC
Mar 20, 2019 | 07:07 EDT
BofA/Merrill analyst Jason Gerberry reinstated Bausch Health with an Underperform and $18 price target. The analyst believes consensus margin expectations are overstating new pharma product launches, which are broadly a niche and highly promotional, and likely a drag on margins.